1. Home
  2. IMMP vs RIV Comparison

IMMP vs RIV Comparison

Compare IMMP & RIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • RIV
  • Stock Information
  • Founded
  • IMMP 1987
  • RIV 2015
  • Country
  • IMMP Australia
  • RIV United States
  • Employees
  • IMMP N/A
  • RIV N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • RIV Finance Companies
  • Sector
  • IMMP Health Care
  • RIV Finance
  • Exchange
  • IMMP Nasdaq
  • RIV Nasdaq
  • Market Cap
  • IMMP 251.8M
  • RIV 266.0M
  • IPO Year
  • IMMP N/A
  • RIV N/A
  • Fundamental
  • Price
  • IMMP $1.68
  • RIV $11.96
  • Analyst Decision
  • IMMP Buy
  • RIV
  • Analyst Count
  • IMMP 1
  • RIV 0
  • Target Price
  • IMMP $7.00
  • RIV N/A
  • AVG Volume (30 Days)
  • IMMP 88.5K
  • RIV 87.6K
  • Earning Date
  • IMMP 10-21-2025
  • RIV 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • RIV 12.85%
  • EPS Growth
  • IMMP N/A
  • RIV N/A
  • EPS
  • IMMP N/A
  • RIV N/A
  • Revenue
  • IMMP $3,306,742.00
  • RIV N/A
  • Revenue This Year
  • IMMP N/A
  • RIV N/A
  • Revenue Next Year
  • IMMP $725.37
  • RIV N/A
  • P/E Ratio
  • IMMP N/A
  • RIV N/A
  • Revenue Growth
  • IMMP 31.28
  • RIV N/A
  • 52 Week Low
  • IMMP $1.32
  • RIV $9.63
  • 52 Week High
  • IMMP $2.71
  • RIV $12.43
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 50.03
  • RIV 40.11
  • Support Level
  • IMMP $1.60
  • RIV $12.09
  • Resistance Level
  • IMMP $1.76
  • RIV $12.36
  • Average True Range (ATR)
  • IMMP 0.06
  • RIV 0.13
  • MACD
  • IMMP 0.01
  • RIV -0.02
  • Stochastic Oscillator
  • IMMP 52.94
  • RIV 2.27

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About RIV RiverNorth Opportunities Fund Inc.

Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.

Share on Social Networks: